Anlotinib Efficacy in Chinese Solid Tumor Patients with Liver Metastases, 2020-2023

A retrospective clinical study of 475 patients with solid tumors and liver metastases treated with anlotinib-based therapy across five centers in China. The data includes primary outcomes like objective response rate and progression-free survival, along with secondary outcomes for hepatic response and overall survival. The study was authored by Yanru Qin and covers patients treated between January 2020 and February 2023.

Use Cases

• Analyze real-world progression-free survival (PFS) and overall survival (OS) for anlotinib therapy based on patient cohort data.
• Compare hepatic-specific response rates (hORR, hPFS) to overall tumor response based on the reported clinical metrics.
• Investigate the association between body mass index (BMI) categories and treatment efficacy based on the reported subgroup analysis.
• Evaluate the safety profile of anlotinib based on the reported incidence and types of adverse events.

Strengths

• Data from 475 patients provides a substantial cohort for analysis.
• Multicenter design involving 5 centers in China suggests geographic diversity within the study.
• Reports specific clinical metrics including median PFS of 5.80 months and OS of 9.53 months.
• Includes subgroup analysis by BMI categories and tumor types.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic and temporal bias inherent to the specific hospitals and study period.

Provenance

Source

Yanru Qin via figshare.

Collection Method

Retrospective review of patient records from 5 medical centers.

Time Range

January 2020 to February 2023.

Freshness

Last updated 2026-05-15 05:41:03; freshness should be verified.

Geography

China.